Celltrion rituximab biosimilar approved; files for IPR of trastuzumab

The European Commission approved Truxima biosimilar rituximab (CT-P10) from the Celltrion Healthcare unit of Celltrion Inc. (KOSDAQ:068270). Truxima is approved for all the same indications as reference product Rituxan/MabThera from Roche (SIX:ROG; OTCQX:RHHBY).

Celltrion did not respond to inquiries regarding launch timing or pricing. The CD20 inhibitor is approved in the EU for non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis...